{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T20:21:27Z","timestamp":1780431687822,"version":"3.54.1"},"reference-count":60,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T00:00:00Z","timestamp":1661299200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005341","name":"Bayerisches Staatsministerium f\u00fcr Wissenschaft, Forschung und Kunst","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005341","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Class 1 and 2 monoclonal antibodies inhibit SARS-CoV-2 entry by blocking the interaction of the viral receptor-binding domain with angiotensin-converting enzyme 2 (ACE2), while class 3 antibodies target a highly conserved epitope outside the ACE2 binding site. We aimed to investigate the plasticity of the spike protein by propagating wild-type SARS-CoV-2 in the presence of class 3 antibody S309. After 12 weeks, we obtained a viral strain that was completely resistant to inhibition by S309, due to successively evolving amino acid exchanges R346S and P337L located in the paratope of S309. The antibody lost affinity to receptor-binding domains carrying P337L or both amino acid exchanges, while ACE2 binding was not affected. The resistant strain replicated efficiently in human CaCo-2 cells and was more susceptible to inhibition of fusion than the original strain. Overall, SARS-CoV-2 escaped inhibition by class 3 antibody S309 through a slow, but targeted evolution enabling immune escape and altering cell entry. This immune-driven enhancement of infectivity and pathogenicity could play an important role in the future evolution of SARS-CoV-2, which is under increasing immunological pressure from vaccination and previous infections.<\/jats:p>","DOI":"10.3389\/fimmu.2022.966236","type":"journal-article","created":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T09:42:59Z","timestamp":1661334179000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":26,"title":["Targeted escape of SARS-CoV-2 in vitro from monoclonal antibody S309, the precursor of sotrovimab"],"prefix":"10.3389","volume":"13","author":[{"given":"Clara Luzia","family":"Magnus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Hiergeist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Schuster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anette","family":"Rohrhofer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Medenbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Gessner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Peterhoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2852-1","article-title":"SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies","volume":"588","author":"Barnes","year":"2020","journal-title":"Nature"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1126\/science.abb7269","article-title":"A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV","volume":"368","author":"Yuan","year":"2020","journal-title":"Science"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2349-y","article-title":"Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody","volume":"583","author":"Pinto","year":"2020","journal-title":"Nature"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1126\/science.abh1139","article-title":"Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants","volume":"373","author":"Yuan","year":"2021","journal-title":"Science"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-04385-3","article-title":"Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies","volume":"602","author":"Cao","year":"2022","journal-title":"Nature"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1126\/science.abl9463","article-title":"Membrane fusion and immune evasion by the spike protein of SARS-CoV-2 delta variant","volume":"374","author":"Zhang","year":"2021","journal-title":"Science"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/d41586-021-03829-0","article-title":"Omicron overpowers key COVID antibody treatments in early tests","author":"Kozlov","year":"2021","journal-title":"Nature"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2022.104076","article-title":"Omicron's binding to sotrovimab, casirivimab, imdevimab, CR3022, and sera from previously infected or vaccinated individuals","volume":"25","author":"Mader","year":"2022","journal-title":"iScience"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1126\/science.abd0831","article-title":"Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies","volume":"369","author":"Baum","year":"2020","journal-title":"Science"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1101\/2021.03.09.434607","article-title":"The dual function monoclonal antibodies VIR-7831 and VIR-7832 demonstrate potent in vitro and in vivo activity against SARS-CoV-2","author":"Cathcart","year":"2021","journal-title":"bioRxiv."},{"key":"B11","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2021.12.046","article-title":"SARS-CoV-2 omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses","volume":"185","author":"Dejnirattisai","year":"2022","journal-title":"Cell"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107934","article-title":"Early treatment for covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab","volume":"385","author":"Gupta","year":"2021","journal-title":"N Engl J Med"},{"key":"B13","unstructured":"CORONAVIRUS (COVID-19) UPDATE: FDA AUTHORIZES ADDITIONAL MONOCLONAL ANTIBODY FOR TREATENT OF COVID-19)2022"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-04594-4","article-title":"Antibody evasion properties of SARS-CoV-2 omicron sublineages","volume":"604","author":"Iketani","year":"2022","journal-title":"Nature"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2022.04.017","article-title":"SARS-CoV-2 omicron sublineages show comparable cell entry but differential neutralization by therapeutic antibodies","volume":"30","author":"Arora","year":"2022","journal-title":"Cell Host Microbe"},{"key":"B16","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-022-01792-5","article-title":"Serum neutralization of SARS-CoV-2 omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies","volume":"28","author":"Bruel","year":"2022","journal-title":"Nat Med"},{"key":"B17","unstructured":"FDA UPDATES SOTROVIMAB EMERGENCY USE AUTHORIZATION2022"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-31615-7","article-title":"Resilience of S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV-2 omicron lineage strains","volume":"13","author":"Case","year":"2022","journal-title":"Nat Commun"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-020-01503-7","article-title":"A highly specific and sensitive serological assay detects SARS-CoV-2 antibody levels in COVID-19 patients that correlate with neutralization","volume":"49","author":"Peterhoff","year":"2021","journal-title":"Infection"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/srep04659","article-title":"A simple, inexpensive method for preparing cell lysates suitable for downstream reverse transcription quantitative PCR","volume":"4","author":"Shatzkes","year":"2014","journal-title":"Sci Rep"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2020.25.3.2000045","article-title":"Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR","volume":"25","author":"Corman","year":"2020","journal-title":"Euro Surveill"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3390\/v13040653","article-title":"Comparison of throat washings, nasopharyngeal swabs and oropharyngeal swabs for detection of SARS-CoV-2","volume":"13","author":"Hitzenbichler","year":"2021","journal-title":"Viruses"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3727\/095535491820873191","article-title":"Use of an aqueous soluble tetrazolium\/formazan assay for cell growth assays in culture","volume":"3","author":"Cory","year":"1991","journal-title":"Cancer Commun"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0261045","article-title":"Coronavirus resistance database (CoV-RDB): SARS-CoV-2 susceptibility to monoclonal antibodies, convalescent plasma, and plasma from vaccinated persons","volume":"17","author":"Tzou","year":"2022","journal-title":"PLoS One"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/16.15.7351","article-title":"A general method of in vitro preparation and specific mutagenesis of DNA fragments: study of protein and DNA interactions","volume":"16","author":"Higuchi","year":"1988","journal-title":"Nucleic Acids Res"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9060642","article-title":"Augmenting the immune response against a stabilized HIV-1 clade c envelope trimer by silica nanoparticle delivery","volume":"9","author":"Peterhoff","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1126\/science.abb2762","article-title":"Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2","volume":"367","author":"Yan","year":"2020","journal-title":"Science"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1126\/science.abd0827","article-title":"Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail","volume":"369","author":"Hansen","year":"2020","journal-title":"Science"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2022.01.006","article-title":"Mutations in SARS-CoV-2 variants of concern link to increased spike cleavage and virus transmission","volume":"30","author":"Escalera","year":"2022","journal-title":"Cell Host Microbe"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.61312","article-title":"Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants","volume":"9","author":"Weisblum","year":"2020","journal-title":"Elife"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1126\/science.abf9302","article-title":"Prospective mapping of viral mutations that escape antibodies used to treat COVID-19","volume":"371","author":"Starr","year":"2021","journal-title":"Science"},{"key":"B32","unstructured":"FACT SHEET FOR HEALTHCARE PROVIDERS EMERGENCY USE AUTHORIZATION (EUA) OF SOTROVIMAB2021"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03925-1","article-title":"Lectins enhance SARS-CoV-2 infection and influence neutralizing antibodies","volume":"598","author":"Lempp","year":"2021","journal-title":"Nature"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2021107821","article-title":"TMPRSS2 expression dictates the entry route used by SARS-CoV-2 to infect host cells","volume":"40","author":"Koch","year":"2021","journal-title":"EMBO J"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1009212","article-title":"Hydroxychloroquine-mediated inhibition of SARS-CoV-2 entry is attenuated by TMPRSS2","volume":"17","author":"Ou","year":"2021","journal-title":"PLoS Pathog"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2021.100306","article-title":"SARS-CoV-2 infects cells after viral entry via clathrin-mediated endocytosis","volume":"296","author":"Bayati","year":"2021","journal-title":"J Biol Chem"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21213-4","article-title":"A genome-wide CRISPR screen identifies host factors that regulate SARS-CoV-2 entry","volume":"12","author":"Zhu","year":"2021","journal-title":"Nat Commun"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-04441-6","article-title":"SARS-CoV-2 omicron virus causes attenuated disease in mice and hamsters","volume":"603","author":"Halfmann","year":"2022","journal-title":"Nature"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2021.103694","article-title":"Increased neutralization of SARS-CoV-2 delta variant after heterologous ChAdOx1 nCoV-19\/BNT162b2 versus homologous BNT162b2 vaccination","volume":"25","author":"Bauswein","year":"2022","journal-title":"iScience"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.06.002","article-title":"The monoclonal antibody combination REGEN-COV protects against SARS-CoV-2 mutational escape in preclinical and human studies","volume":"184","author":"Copin","year":"2021","journal-title":"Cell"},{"key":"B41","unstructured":"FACT SHEET FOR HEALTH CARE PROVIDERS EMERGENCY USE AUTHORIZATION (EUA) OF REGEN-COV\u00ae(casirivimab and imdevimab)2021"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1101\/2022.04.06.487325","article-title":"Delta-omicron recombinant SARS-CoV-2 in a transplant patient treated with sotrovimab","author":"Duerr","year":"2022","journal-title":"bioRxiv"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2120219","article-title":"Resistance mutations in SARS-CoV-2 delta variant after sotrovimab use","volume":"386","author":"Rockett","year":"2022","journal-title":"N Engl J Med"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/S2666-5247(22)00120-3","article-title":"Sotrovimab drives SARS-CoV-2 omicron variant evolution in immunocompromised patients","volume":"3","author":"Destras","year":"2022","journal-title":"Lancet Microbe"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1101\/2022.04.06.22273503","article-title":"High incidence of sotrovimab resistance and viral persistence after treatment of immunocompromised patients infected with the SARS-CoV-2 omicron variant","author":"Huygens","year":"2022","journal-title":"medRxiv."},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-021-00985-w","article-title":"Comprehensive mapping of binding hot spots of SARS-CoV-2 RBD-specific neutralizing antibodies for tracking immune escape variants","volume":"13","author":"Yi","year":"2021","journal-title":"Genome Med"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03291-y","article-title":"SARS-CoV-2 evolution during treatment of chronic infection","volume":"592","author":"Kemp","year":"2021","journal-title":"Nature"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03807-6","article-title":"SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape","volume":"597","author":"Starr","year":"2021","journal-title":"Nature"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.46234\/ccdcw2021.255","article-title":"GISAID's role in pandemic response","volume":"3","author":"Khare","year":"2021","journal-title":"China CDC Wkly."},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/s41580-021-00418-x","article-title":"Mechanisms of SARS-CoV-2 entry into cells","volume":"23","author":"Jackson","year":"2022","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.3001006","article-title":"SARS-CoV-2 variants reveal features critical for replication in primary human cells","volume":"19","author":"Pohl","year":"2021","journal-title":"PLoS Biol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-020-00763-0","article-title":"Characterisation of the transcriptome and proteome of SARS-CoV-2 reveals a cell passage induced in-frame deletion of the furin-like cleavage site from the spike glycoprotein","volume":"12","author":"Davidson","year":"2020","journal-title":"Genome Med"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2020.1756700","article-title":"Attenuated SARS-CoV-2 variants with deletions at the S1\/S2 junction","volume":"9","author":"Lau","year":"2020","journal-title":"Emerg Microbes Infect"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23166-0","article-title":"Characterization of an attenuated SARS-CoV-2 variant with a deletion at the S1\/S2 junction of the spike protein","volume":"12","author":"Wang","year":"2021","journal-title":"Nat Commun"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1009233","article-title":"SARS-CoV-2 variants with mutations at the S1\/S2 cleavage site are generated in vitro during propagation in TMPRSS2-deficient cells","volume":"17","author":"Sasaki","year":"2021","journal-title":"PLoS Pathog"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01294-w","article-title":"Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies","volume":"27","author":"Chen","year":"2021","journal-title":"Nat Med"},{"key":"B57","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.09.033","article-title":"SARS-CoV-2 infection depends on cellular heparan sulfate and ACE2","volume":"183","author":"Clausen","year":"2020","journal-title":"Cell"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2003138117","article-title":"Cell entry mechanisms of SARS-CoV-2","volume":"117","author":"Shang","year":"2020","journal-title":"Proc Natl Acad Sci USA"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1099\/0022-1317-83-9-2091","article-title":"Occupancy and mechanism in antibody-mediated neutralization of animal viruses","volume":"83","author":"Klasse","year":"2002","journal-title":"J Gen Virol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01255-3","article-title":"Sixteen novel lineages of SARS-CoV-2 in south Africa","volume":"27","author":"Tegally","year":"2021","journal-title":"Nat Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.966236\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T09:43:07Z","timestamp":1661334187000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.966236\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,24]]},"references-count":60,"alternative-id":["10.3389\/fimmu.2022.966236"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.966236","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,24]]},"article-number":"966236"}}